Our present study proved that SIRT7 plays an oncogenic factor in melanoma by synergistically modulating tumor cell survival and anti-tumor immune surveillance, underpinning SIRT7 as a promising therapeutic target, as well as extending the spectrum of cancers that SIRT7 plays a pathogenic role in. This evidence concerns the gene SIRT7 and melanoma.